IP Update

Premium

Title: RNA Interference Agents for Therapeutic Use

Patent Number: 7,951,784

Filed: Jan. 26, 2007

Lead Inventor: Tariq Rana, University of Massachusetts (RXi Pharmaceuticals)

“The invention features chemically modified small interfering RNAs that are stable in vivo and retain the ability to form an A-form helix when in association with a target RNA,” the patent's abstract states. “The featured siRNA are effective therapeutics, particularly for targeting SOD1.”

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.

The New York Times examines ethics and China's push to lead biomedical research.